Compare Johnson & Johnson (JNJ) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Nutrien Ltd — how do they compare? Johnson & Johnson trades at $249.37 (market cap $598.96B), while Nutrien Ltd trades at $67.02 (market cap $31.67B). The key difference: Johnson & Johnson is far larger — about 18.9× Nutrien Ltd's market cap, and Nutrien Ltd pays the higher dividend (3.3%). Which is the better fit depends on your goals.
| JNJ | NTR | |
|---|---|---|
Market Cap | $598.96B | $31.67B |
Volume | 6,156,228 | — |
Sector | Health | Basic Materials |
52-Week High | $267.24 | $83.94 |
52-Week Low | $164.36 | $53.64 |
Enterprise Value | $631.90B | $44.84B |
Dividend Yield | 2.15% | 3.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Nutrien (NTR) trades at $66.40, down 1.31% on the day, with a bullish technical outlook supported by moving averages. The company shows improving fundamentals with Q1 2026 EPS beating expectations at $0.51 versus $0.48, and revenue trending upward to $26.89B in 2025. Valuation ratios appear attractive with a P/E of 13.7 and P/S of 1.17. Analyst sentiment is positive with a consensus price target of $77.67, representing 17% upside, and 61% of analysts rate it a Buy.
The outlook for Nutrien is favorable due to strong fertilizer demand and cost management, though risks include volatile input costs and competitive pressures. With solid cash flow from operations and a dividend payout, the stock offers value and income potential, but investors should monitor global agricultural trends and energy market impacts on margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
